



Autolus Therapeutics Submits Fiscal Year 2018 Form 20-F

November 23, 2018

LONDON, Nov. 23, 2018 /PRNewswire/ -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended 2018 with the United States Securities and Exchange Commission. The annual report can be found on Autolus' investor relations website at <https://www.autolus.com/investor-relations/financial-information/sec-filings>.

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: <https://www.autolus.com>

Investor contact:

S.A. Noonan Communications
Susan A. Noonan
+1-212-966-3650
susan@sanoonan.com

International Media Contact:

JW Communications
Julia Wilson
+44 (0)7818 430877
juliawilsonuk@gmail.com

U.S. Media Contact:

Rx Communications Group, LLC
Paula Schwartz
+ 1-917-322-2216
pschwartz@rxir.com

 View original content: <http://www.prnewswire.com/news-releases/autolus-therapeutics-submits-fiscal-year-2018-form-20-f-300754699.html>

SOURCE Autolus Therapeutics plc